COMPANY

Serina Therapeutics

Location: Alameda, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Advanced Parkinson's Disease Parkinson's Disease SER-252 (PEOZ-apomorphine) SER-214

Timeline

Feb 1, 2026 Trial start Phase 1: SAD Study in Patients With Parkinson's Disease and Motor Fluctuations source ↗
Apr 8, 2025 Raise Private equity round: $5M (total, as published), announced Apr 8, 2025. Source: company release on GlobeNewswire. source ↗
Dec 2, 2024 Raise Private equity round: $10M (total, as published), announced Dec 2, 2024. Source: company release on GlobeNewswire. source ↗
2016-01 Trial start Phase 1: A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 source ↗

Jan 31, 2027 (ESTIMATED) · Phase 1 · SAD Study in Patients With Parkinson's Disease and Motor Fluctuations · NCT07422675

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $15.0M. Last 2 years.

Apr 8, 2025 Private equity round: $5M (total, as published), announced Apr 8, 2025. Source: company release on GlobeNewswire. source ↗
Dec 2, 2024 Private equity round: $10M (total, as published), announced Dec 2, 2024. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07422675	SAD Study in Patients With Parkinson's Disease and Motor Fluctuations	Phase 1	Recruiting	Feb 1, 2026	Jan 31, 2027 (estimated)
NCT02579473	A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214	Phase 1	Unknown status (ClinicalTrials.gov)	2016-01	Dec 31, 2023 (estimated)